
Kauffman Fellows • Venture Fund Portfolio Construction | Journal | Kauffman Fellows
Essentially, founders see themselves getting diluted during each subsequent financing. Although dilution is a typical part of each subsequent round of financing, they sometimes want to be awarded options for their role as employees. If they do, the founders should be prepared to raise the bar and tie additional options awards to improved performanc
... See moreAlex Wilmerding • Term Sheets & Valuations: A Line by Line Look at the Intricacies of Term Sheets & Valutions (Bigwig Briefs)
This higher risk level in health/pharma companies shows up in the way VCs structure their investments. In an early-stage round of financing for a software company, all the investors may dilute the founders by around 15 to 30 percent of the company’s stock. For a typical early-stage pharma or biotech company, investors may dilute the founders at a h
... See more